Vivanza Biosciences share price
BSE: 530057Pharmaceuticals & BiotechnologySmall Cap
Vivanza Biosciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995
Last close ₹1.54up ₹0.11 (7.69%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹1.43.
30 Oct: open ₹1.50, high ₹1.60, low ₹1.50
52-week range of traded prices to 30 Oct 2026
₹1.30Low, 26 Oct 2026₹2.72High, 17 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6.16 Cr4,790th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.57
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.41
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 2.34
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 24,333
Results
Consolidated; ₹ crore.Vivanza Biosciences quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +735.0%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹9.29 Crup 46.00%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹0.15 CrQuarter to Mar 2026: −₹0.45 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 1.6%
Revenue by quarter
Peak revenue ₹55 Cr, quarter to Sep 2025; lowest ₹0.48 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
Back to profit in the quarter to Jun 2026, ₹0.15 CrA loss in 2 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.0 | 1.5 | 0.5 | 8.9 | 55.4 | 45.3 | 6.4 | 9.3 |
| Net profit | 0.0 | 0.0 | −1.0 | 0.1 | 0.6 | 0.2 | −0.5 | 0.1 |
| Net margin | 0.5% | 2.9% | −206.6% | 1.0% | 1.0% | 0.4% | −7.1% | 1.6% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹116 Crup 1,461.44%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.39 CrYear to Mar 2025: −₹0.67 Cr
- Net margin
- 0.3%
Revenue by year
Peak revenue ₹116 Cr, year to Mar 2026; lowest ₹2.66 Cr, year to Mar 2019
Net profit by year, a loss in red
- Net profit
- Loss
Back to profit in the year to Mar 2026, ₹0.39 CrA loss in 4 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 6 | 3 | 10 | 10 | 10 | 18 | 28 | 7 | 116 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | −1 | 0 |
| Net margin | −8.9% | 3.2% | −16.6% | −2.1% | 0.8% | 3.2% | 3.4% | 2.0% | −9.1% | 0.3% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Business of Pharmaceuticals and Agro trading and consultancy related activities, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Vivanza Biosciences PE ratio and valuation
Price to book
At or below today's level on 0.4% of 946 trading days over the last 5 years.
LowestHighest
Its median3.07Industry median2.89
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −11.6% | – | – | 0.0% |
| 3 years | −54.6% | −13.0% | −47.8% | 0.0% |
| 5 years | −33.0% | +39.4% | −52.0% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Vivanza Biosciences competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Vivanza Biosciences in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Beryl DrugsBERLDRG | 13 | 20.79 | 1.31 | +8.3% | +169.1% | 6.4% | 3.1% | 0.00% |
 Unjha FormulationsUNJHAFOR | 13 | 27.03 | 3.32 | +13.0% | +386.7% | 13.5% | 15.2% | 0.00% |
 Ortin GlobalORTINGLOBE | 11 | – | 8.77 | −58.3% | – | −56.2% | −52.2% | 0.00% |
 Dipna PharmachemDPL | 10 | – | – | – | – | – | – | 0.00% |
 Brawn BiotechBRAWN | 7 | 8.60 | 1.70 | +13.6% | – | 22.3% | −12.6% | 0.00% |
 Decipher LabsDECIPHER | 5 | – | 0.63 | −25.2% | – | – | −31.5% | 0.00% |
 Advik LaboratoriesADVIKLA | 4 | – | 58.03 | – | – | −180.6% | −14.5% | 0.00% |
 Shyama Computronics and ServicesSHYAMACOMP | 4 | – | 0.35 | +9.4% | – | – | 0.6% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Vivanza Biosciences announcements
Oct 2026
29 Oct · Non-Applicability Of Regulation 23(9) Of SEBI (LODR) Regulations, 2015 Regarding Submission Of Disclosures Of Related Party Transactions For The Half Year Ended On September 30, 2026
28 Oct · Board meeting
Meeting on 3 Nov 2026: quarterly results
Sep 2026
12 Sep · Meeting
Vivanza Biosciences share price by year
Each calendar year to 2025.Vivanza Biosciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2.20 | −35.7% | 3.85 | 1.96 |
| 2024 | 3.42 | −68.2% | 11.24 | 3.24 |
| 2023 | 10.77 | −31.0% | 20.78 | 7.17 |
| 2022 | 15.60 | −12.9% | 19.50 | 12.16 |
| 2021 | 17.92 | +59.7% | 21.00 | 6.34 |
| 2020 | 11.22 | +731.1% | 11.22 | 1.25 |
| 2019 | 1.35 | −44.3% | 2.31 | 1.35 |
| 2018 | 2.43 | −62.6% | 7.50 | 2.43 |
| 2017 | 6.48 | −53.8% | 19.13 | 6.48 |
| 2016 | 14.02 | +123.5% | 14.50 | 4.50 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. The close is the year's last trade for 2018 (30 Nov 2018) and 2017 (13 Dec 2017).
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 29 Oct 2026 | 1.50 | 1.50 | 1.43 | 1.43 | 1.49 | 18,847 |
| 28 Oct 2026 | 1.55 | 1.55 | 1.50 | 1.50 | 1.50 | 8,823 |
| 27 Oct 2026 | 1.51 | 1.60 | 1.51 | 1.56 | 1.52 | 13,819 |
| 26 Oct 2026 | 1.30 | 1.56 | 1.30 | 1.43 | 1.47 | 12,293 |
| 23 Oct 2026 | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 | 3,075 |
| 22 Oct 2026 | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 | 3,680 |
| 21 Oct 2026 | 1.69 | 1.69 | 1.64 | 1.64 | 1.65 | 10,744 |
| 19 Oct 2026 | 1.70 | 1.70 | 1.41 | 1.69 | 1.52 | 8,473 |
| 16 Oct 2026 | 1.60 | 1.70 | 1.60 | 1.70 | 1.67 | 31,732 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 24 Mar 2023 | Split | 0.1000 | Each share became 10. |
| 20 Aug 2015 | Price move | – | This is the share's first trade after a corporate action (Reduction of Capital, ex-date 27 May 2015), and the action's terms do not account for the move. Earlier prices are not shown. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Where an event has no factor that can be worked out, the chart leaves out the closes before it.
Company details
- BSE code
- 530057
- ISIN
- INE984E01035
- Industry
- Pharmaceuticals & Biotechnology
- Website
- vivanzabiosciences.com
- CIN
- L24110GJ1982PLC005057
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1982
- Registered office
- 403, Sarthik 2, Opp. Rajpath Club, S G Highway, Ahmedabad 380054, Gujarat
- Share registrar
- Purva Sharegistry (India) Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments